New Tool to Check Up-to-Date Status
 |
|
MDHHS has released a new tool for the public to help determine if they are up to date on COVID-19 vaccine, or if it is time for a booster or additional primary dose.
Visit Michigan.gov/COVIDVaccineUpToDateTool to check your status.
|
Expanded Eligibility Criteria for COVID-19 Therapeutics
Until recently, options for outpatient therapies for patients with mild to moderate COVID-19 have often been in limited supply, necessitating prioritizing eligibility to those at higher risk. As current COVID-19 activity declines and with increasing medication supply, there is no longer a need for limiting eligibility beyond the requirements established by the Food and Drug Administration (FDA). In the event of future COVID-19 surges and/or reductions in supply, prioritization may need to be reestablished.
Clinicians caring for COVID-19 patients should be aware of the availability of these important life-saving medications and consider their use when clinically indicated.
MDHHS has updated Guidance for Outpatient Therapies for Patients with Mild to Moderate COVID-19 to align with the current FDA recommendations.
COVID-19 Therapeutics Clinical Updates
Evusheld
- The U.S. Food and Drug Administration has revised the emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab) to change the initial dose for the authorized use as pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric patients.
- The initial dose of Evusheld has been changed to 300 mg of tixagevimab and 300 mg of cilgavimab administered as two separate consecutive intramuscular injections.
- Patients who have already received the previously authorized dose (150 mg of tixagevimab and 150 mg of cilgavimab) should receive an additional dose of 150 mg of tixagevimab and 150 mg of cilgavimab as soon as possible to raise their monoclonal antibody levels to those expected for patients receiving the higher dose.
- Health care professionals should contact patients who received the previously authorized Evusheld dose to return for an additional 150 mg tixagevimab and 150 mg cilgavimab dose as soon as possible.
- Evusheld may need to be redosed due to efficacy against the SARS-CoV-2 variants circulating in the U.S. Because it is unclear which SARS-CoV-2 variant or Omicron subvariant will become dominant in the U.S. over the next few months, the recommended timing for repeat dosing cannot be provided at this time.
The Fact Sheet will be revised with repeat dosing recommendations in the future when more data are available to determine the appropriate timing of redosing.
Sotrovimab
- Sotrovimab must now be administered within 7 days of symptom onset per the Emergency Use Authorization. This has been reduced from the previous 10 days recommendation. See the Sotrovimab Fact Sheet for Health Care Providers for additional information.
COVID-19 Vaccine Data
 The Michigan First-Dose Tracker* has been updated to track doses for the entire Michigan population. As of March 1, 66.1% of eligible Michigan residents have had at least one dose of the COVID-19 vaccine. A total of 11,380,346 primary doses have been administered in Michigan as of February 28.
* Progress is based on the CDC data tracker, which includes MI residents vaccinated by providers not currently reporting to the state dashboard: Veterans Affairs, Department of Defense, Bureau of Prisons, and most out-of-state providers.
|
